Physician profile
Marisa Sandera
NPI 1508828971
$17,388.26
in general payments reported to CMS, 2019-2025
72 companies · $3,624 in 2025
The $3,624 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,345 · 2020: $1,652 · 2021: $1,964 · 2022: $2,351 · 2023: $2,867 · 2024: $2,585 · 2025: $3,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,567 · Consulting Fee: $450 · Education: $59.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,566.51 |
| Consulting Fee | $450.00 |
| Education | $59.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,240.76 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $1,077.09 | 2020-2025 | Xpovio |
| Astrazeneca Pharmaceuticals Lp | $1,064.29 | 2019-2025 | Enhertu, Calquence, Tagrisso |
| Gilead Sciences, INC. | $980.38 | 2019-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $905.29 | 2019-2025 | |
| Pfizer INC. | $875.24 | 2019-2025 | |
| Janssen Biotech, INC. | $770.93 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| E.R. Squibb & Sons, L.L.C. | $743.16 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $634.26 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Eisai INC. | $599.15 | 2019-2025 | |
| Daiichi Sankyo INC. | $563.77 | 2020-2025 | Injectafer, Enhertu, Datroway |
| Genzyme Corporation | $533.96 | 2019-2025 | |
| Genentech USA, INC. | $533.75 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Amgen INC. | $506.81 | 2019-2022 | |
| Seagen INC. | $441.58 | 2019-2023 | Tukysa |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $394.74 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Regeneron Healthcare Solutions, INC. | $390.95 | 2019-2025 | Libtayo, Lynozyfic |
| Puma Biotechnology, INC. | $381.44 | 2019-2025 | |
| Incyte Corporation | $378.35 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Genmab U.S., INC. | $352.64 | 2023-2025 | Epkinly |
| Astellas Pharma US INC | $339.12 | 2019-2025 | Vyloy, Padcev, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $277.06 | 2021-2025 | Fruzaqla, Iclusig, Ninlaro |
| Rigel Pharmaceuticals, INC. | $262.49 | 2019-2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $252.90 | 2019-2024 | |
| Abbvie INC. | $212.09 | 2019-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $168.16 | 2023-2025 | |
| Emd Serono, INC. | $140.75 | 2019-2023 | Bavencio |
| Jazz Pharmaceuticals INC. | $124.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $115.35 | 2022-2025 | Blenrep, Jemperli |
| Pharmacosmos Therapeutics INC. | $113.09 | 2021-2022 | |
| Adc Therapeutics America, INC. | $110.46 | 2022-2024 | |
| Stemline Therapeutics INC. | $100.92 | 2023-2025 | Orserdu |
| Spectrum Pharmaceuticals INC. | $92.92 | 2023-2025 | Rolvedon |
| Pharmaessentia USA Corporation | $88.66 | 2023-2024 | Besremi |
| Mirati Therapeutics, INC. | $87.56 | 2023-2024 | Krazati |
| Dova Pharmaceuticals | $83.21 | 2020-2021 | |
| Beigene USA, INC. | $81.99 | 2020-2024 | Brukinsa |
| Array Biopharma INC | $77.36 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Apellis Pharmaceuticals, INC. | $76.68 | 2023-2025 | Empaveli |
| Kyowa Kirin, INC. | $75.24 | 2019-2024 | Poteligeo |
| Cti Biopharma Corp. | $72.87 | 2022-2023 | Vonjo |
| Kite Pharma, INC. | $71.76 | 2022-2025 | Yescarta |
| Exelixis INC. | $70.49 | 2019-2021 | |
| Servier Pharmaceuticals LLC | $65.88 | 2021-2024 | |
| Deciphera Pharmaceuticals INC. | $60.28 | 2024-2025 | Qinlock, Romvimza |
| Aveo Pharmaceuticals, INC. | $54.05 | 2021-2023 | Fotivda |
| Coherus Oncology, INC. | $50.07 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $48.63 | 2019-2023 | Somatuline Depot, Onivyde |
| Sumitomo Pharma America, INC. | $47.02 | 2023-2025 | Orgovyx |
| Heron Therapeutics, INC. | $41.20 | 2019 | |
| Blueprint Medicines Corporation | $40.95 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $40.24 | 2022 | |
| Verastem, INC. | $36.89 | 2019 | |
| Morphosys, US INC. | $35.05 | 2022 | |
| Amneal Pharmaceuticals LLC | $33.84 | 2023-2024 | Neupogen, Neulasta, Avastin |
| Pharmacyclics LLC, An Abbvie Company | $33.16 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.93 | 2019-2020 | |
| Secura Bio, INC. | $28.43 | 2020 | |
| Fresenius Kabi USA, LLC | $27.82 | 2025 | Stimufend |
| Agios Pharmaceuticals, INC. | $23.31 | 2024 | |
| Sobi, INC | $23.26 | 2023 | |
| Verity Pharmaceuticals INC. | $22.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.79 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.68 | 2022 | |
| Octapharma USA, INC. | $20.00 | 2023 | Octagam Immune Globulin (Human) |
| Springworks Therapeutics, INC. | $19.98 | 2025 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $19.96 | 2025 | Danziten |
| Geron Corporation | $19.60 | 2025 | Rytelo |
| Helsinn Therapeutics (U.S.), INC. | $18.96 | 2019 | |
| Clovis Oncology, INC. | $15.01 | 2022 | |
| Epizyme, INC. | $13.50 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Sandera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.